Participant flow

Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide · Source last updated 2016-09-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Busulfan starting dose of 32 mg/m\^2 by vein over 3 hours each day. Test dose day -8 (inpatient) or test dose day -30 to day -8 (outpatient) and then, days -6,-5,-4, and -3. Fludarabine dose of 40 mg/m\^2 by vein over 1 hour each day on Day -6 through Day -3 before receiving Busulfan. Cyclophosphamide dose of 50 mg/kg by vein over 3 hours on Days 3 and 4.

   id

   FG000

   title

   Busulfan + Fludarabine + Cyclophosphamide

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         56

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         49

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         7

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

Recruitment Period: September 02, 2008 to December 12, 2011. All recruitment was done at The University of Texas (UT) MD Anderson Cancer Center.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice